Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes
Reps will be promoting Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes.
Tradjenta (linagliptin) is a "me too"...similar to Onglyza (saxagliptin) and Januvia (sitagliptin). These prolong incretin activity to stimulate insulin and reduce glucagon release.
Tradjenta's only real claim to fame is that it doesn't require a lower dose for patients with impaired renal function.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote